Results In total, 256 (12

Results In total, 256 (12.6%) individuals of the 2032 acute ischemic stroke cohort included in this study had a analysis of NVAF and were taking NOACs. thrombotic, Amiodarone proatherogenic, and proinflammatory factors in addition to the embolic factors associated with atrial fibrillation. Consequently, solely taking fresh oral anticoagulants is definitely insufficient in protecting this group of individuals from ischemic stroke. 0.05. All computations were performed using licensed Statistica 13.0 software (StatSoft, Tulsa, Okay, USA). 3. Results In total, 256 (12.6%) individuals of the 2032 acute ischemic stroke cohort included in this study had a analysis of NVAF and were taking NOACs. The median age of all individuals was 71 years (69.9 8.7 years). In total, 958 individuals (47.15%) were male. Hypertension was present in 1543 individuals (75.94%), diabetes mellitus in 685 (33.71%), dyslipidemia in 876 (43.11%), ICA significant stenosis/occlusion in 298 (14.67%), coronary heart disease in 873 (42.96%), peripheral arterial disease in 262 (12.89%), previous stroke in 954 (46.95%), and cigarette smoking in 1041 (51.23%). 3.1. Assessment of Risk Factors for Ischemic Stroke in Individuals with Nonvalvular Atrial Fibrillation Treated with New-Generation Dental Anticoagulants versus Individuals without Atrial Fibrillation A comparison of both organizations is definitely shown in Table 1. Table 1 Baseline characteristics of individuals with ischemic stroke with nonvalvular atrial fibrillation treated with fresh oral anticoagulants and individuals without atrial fibrillation. = 256)= 1776)(%)181 (70)893 (50) 0.001Comorbidities, (%)Diabetes mellitus134 (52)551 (31) 0.001Dyslipidemia152 (59)724 (40) 0.001Hypertension237 (92)1306 (73) 0.001ICA significant stenosis/occlusion43 (16)255 (14)0.302Coronary heart disease166 (64)707 (39) 0.001Peripheral arterial disease51 (19)211 (11) 0.001Smoking151 (58)890 (50)0.008Previous stroke161 (62)793 (44) 0.001 Open in a separate window Story: em n /em quantity of individuals, Amiodarone SDstandard deviation, Memedian, AFatrial fibrillation, ICA internal carotid artery, NOACnonvalvular atrial fibrillation treated with fresh oral anticoagulants. 3.2. Analysis of Risk Factors for SERPINE1 Ischemic Stroke in Individuals with Nonvalvular Atrial Fibrillation Treated with a New Dental Anticoagulant and Individuals without Atrial Fibrillation A univariate and multivariate logistic regression model is definitely shown in Table 2. Table 2 Analysis of risk factors of ischemic stroke in individuals with atrial fibrillation, who suffered a stroke despite NOAC therapy, compared to individuals without AF (multivariate logistic regression). thead th rowspan=”2″ colspan=”2″ align=”center” valign=”middle” style=”border-top:solid thin;border-bottom:solid thin” Factors /th th colspan=”4″ align=”center” valign=”middle” style=”border-top:solid thin;border-bottom:solid thin” rowspan=”1″ Univariable Logistic Regression Models /th th colspan=”4″ align=”center” valign=”middle” style=”border-top:solid thin;border-bottom:solid thin” rowspan=”1″ Multivariable Logistic Regression Magic size * /th th align=”center” valign=”middle” style=”border-bottom:solid thin” rowspan=”1″ colspan=”1″ OR Amiodarone /th th align=”center” valign=”middle” style=”border-bottom:solid thin” rowspan=”1″ colspan=”1″ Cl 95% /th th align=”center” valign=”middle” style=”border-bottom:solid thin” rowspan=”1″ colspan=”1″ Cl 95% /th th align=”center” valign=”middle” style=”border-bottom:solid thin” rowspan=”1″ colspan=”1″ em p /em /th th align=”center” valign=”middle” style=”border-bottom:solid thin” rowspan=”1″ Amiodarone colspan=”1″ OR /th th align=”center” valign=”middle” style=”border-bottom:solid thin” rowspan=”1″ colspan=”1″ Cl 95% /th th align=”center” valign=”middle” style=”border-bottom:solid thin” rowspan=”1″ colspan=”1″ Cl 95% /th th align=”center” valign=”middle” style=”border-bottom:solid thin” rowspan=”1″ colspan=”1″ em p /em /th /thead Age1.161.141.18 00011.221.181.25 0.001GenderFemale2.381.793.17 0.0011.931.372.70 0.001Male1.00 1.00 Diabetes mellitusYes2.441.873.18 0.0011.901.382.63 0.001No1.00 1.00 DyslipidemiaYes2.121622.77 0.0012.481.803.42 0.001No1.00 1.00 HypertensionYes4.482.787.24 0.0014.202.487.10 0.001No1.000 1.00 Coronary heart diseaseYes2.782.123.66 0.0011.791.272.510.001No1.00 1.00 Peripheral arterial diseaseYes1.841.312.58 0.0011.110.721.710.634No1.00 1.00 SmokingYes1.431.091.860.0082.671.913.74 0.001No1.00 1.00 Previous strokeYes2.101.602.75 0.0010.390.260.60 0.001No100 1.00 Open in a separate window Legend: ORodds ratio, CIconfidence interval. * Notice: Model was modified for the following variables: age, sex, diabetes mellitus, dyslipidemia, hypertension, coronary heart disease, peripheral arterial disease, smoking, previous stroke. 4. Discussion The most common therapeutic option for the prevention of ischemic stroke in individuals with AF is definitely treatment with VKA or NOACs. Chronic use of oral anticoagulants reduces the risk of ischemic stroke by 64% [28]. However, this does not completely prevent the risk of ischemic stroke in these individuals. In VKA treatment, one popular explanation for this is definitely that the patient did not follow the physicians recommendations concerning the rate of recurrence of administration, resulting in nontherapeutic international normalized percentage (INR). However, this cannot be the case for.